Budding small business owners stuck in limbo amid cannabis license delays
Eric Taubel, Interim Director at the Office of Cannabis Management, said licenses will be issued in the coming weeks, thanks to recently released rules.
To the dismay of small business owners, retail shop licensing continues to be delayed.
Andrew Caruthers, the owner of Twin Cities High in Golden Valley, opened his shop in 2023, selling CBD and THC products.
In preparation to sell marijuana, he has spent $50,000 to get ready, but now it's the waiting game to start selling.
"I initially was thinking possibly six months, you know, I thought summer of last year we would be open almost for sure" said Caruthers.
When he gets a license, he worries about product shortages and high costs. All marijuana sold legally in the state must be grown in Minnesota.
The Office of Cannabis Management estimates 1.5 million square feet of growing area is needed. Minnesota only has 69,000 square feet available.
"I am anticipating a slow rollout. Maybe we will have product for a few days, and then sell out, and we may not get more for a couple of weeks." said Caruthers, "It's like that everywhere it's become legal, the prices definitely start out."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Why Curaleaf Stock Was Tumbling on Tuesday
Key Points A draft document on President Trump's desk recommends an initiative that would include emphasizing the dangers of substances like THC. To a degree, this counters recent legislative attempts at essentially legalizing marijuana. 10 stocks we like better than Curaleaf › Investors weren't getting much of a buzz from American cannabis stock Curaleaf's (OTC: CURLF) on the second trading day of the week. In late-session action, the shares had lost more than 3% of their value, on discouraging news about one man who can make a powerful push toward legalization if he chooses to do so. The S&P 500 (SNPINDEX: ^GSPC), meanwhile, at that point was down by only 0.7%. Proposals on the table President Donald Trump is reviewing a draft document detailing recommendations on promoting health in American youth, several media outlets reported that day. Among the suggestions is that the U.S. Surgeon General "will launch an education and awareness initiative on the impact of alcohol, controlled substances, vaping, and THC on children's health." THC is the psychoactive compound in cannabis that gets users high. The language suggests that such an initiative would focus on the risks and potentially harmful effects of these substances. As current legislative efforts to reschedule marijuana are focused on a "rescheduling" of the drug that would make it de facto legal throughout the U.S., this document feels like a step in the opposite direction. It is currently unknown if Trump has conducted his review. He has not yet commented on it. Getting Trumped? Although the president has leaned toward marijuana legalization, recently he has indicated a desire to leave it up to individual states to decide, rather than enact reform on the federal level. This would basically maintain the status quo, which is a patchwork of states that have enacted some degree of legalization, mixed with a handful that have kept the drug fully illegal. This won't help the cannabis industry, which in my view can only improve significantly with de facto legalization, in addition to reform that allows it to directly access basic financial services. Should you buy stock in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,076% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Curaleaf Stock Was Tumbling on Tuesday was originally published by The Motley Fool
Forbes
a day ago
- Forbes
Meet The Ex-NASA Engineer Training Robots To Make Pre-Roll Joints
I nside the Los Angeles headquarters of Stiiizy, America's largest cannabis brand by sales, a robotic machine takes ten pre-rolled joints in its arm, dips them into a vessel of THC concentrate and then into another bucket filled with kief, a potent dust-like form of cannabis. In a few seconds, the Stardust machine, made by Van Nuys-based Sorting Robotics, will have coated 30 pre-rolls with an extra punch of THC, the compound in marijuana known for getting people high. In an hour, Stardust, and its one human operator, will have produced about 1,000 joints ready for consumption. 'This machine's output could be more than ten people,' says James Kim, the CEO and cofounder of Stiiizy, while standing next to the Stardust in early April. In another room down the hall, about 140 employees sit at 14 tables, manually dipping joints into a terpene-infused adhesive and rolling them into a pile of kief. Stiiizy isn't ready to replace its humans just yet, but Kim does envision a day when all of its joints will be made entirely by machines. 'Robotics is the future, but the future isn't today,' says Kim. 'It might take a lot more time.' That future is being pioneered by Sorting Robotics, founded by Nohtal Partansky (its CEO), Cassio Santos (CTO) and Sean Lawlor (who was the COO before leaving last year), in 2019. The company has sold about 30 Stardust machines, which go for a hefty $250,000 each, as well as hundreds of lower priced marijuana machines to cannabis brands since its founding. Sorting Robotics also makes the Jiko, which injects joints with THC concentrate, making what's called a 'donut' in pothead lingo (when the joint is lit, the ember resembles an 'O' as the concentrate vaporizes in the middle as the plant material burns.), and the Omnifiller, a vape cartridge-filling machine. The company, which has 20 employees, is still tiny—it will reach $11 million in revenue this year, up from $7 million last year—but Partansky, like many cannabis entrepreneurs, is playing the long game, hoping the drug will eventually be legal at the federal level. The company does have something going for it: profitability. Sorting Robotics has been in the black since 2021. While Stiiizy ($800 million in 2024 sales) is America's largest weed brand, Sorting Robotics' client list also boasts bigger companies by global footprint, including Canada-based Tilray ($788 million in 2024 revenue), and smaller regional outfits in the U.S. such as Blue Fox Brands (sales: $80 million), which sells its pre-roll brand Cali Blaze across Colorado, Massachusetts and Michigan. 'Stardust allows you to replace the labor that you already have with something that's five to 10 times more efficient,' says the 35-year-old Partansky. 'It [can] improve your margins by 10-plus percent.' In the complex world of the state-regulated cannabis, which generated $32 billion in sales last year in the 40 U.S. states that allow medical, recreational or both, better margins can be life-or-death. Only 27% of marijuana businesses are profitable. Most companies fail. Pre-rolled joints are the third biggest product segment in terms of market share (after flower and vape pens) accounting for 16% of all cannabis sales, according to a report by Headset, a Seattle-based cannabis data firm. It is also the fastest-growing category in the industry: In total, 394 million individual joints were sold last year, for $4.1 billion, a 12% jump over 2023. More than 43% of all pre-rolled joints are infused with extra THC, which explains Sorting Robotics focus on the subcategory. But questions remain about how much the market can expand in the short term. Currently, there are only a handful of cannabis companies that produce enough THC-infused pre-rolled joints to make a $250,000 investment like the Stardust make sense financially. Since marijuana is still illegal at the federal level, state-regulated cannabis companies cannot ship product over state lines, meaning products sold in a state must be made in that state, hamstringing manufacturers from creating one giant facility and shipping across the country. And there is good reason companies still employ janitors to sweep floors despite the invention of the Roomba and commercial versions of robotic sweepers like Avidbots' Neo. Robots are expensive and finicky while laborers are cheap and require minimal training. That $250,000 price tag does not include maintenance or operating costs. At Blue Fox Brands's manufacturing facility in Lansing, Michigan, Sorting Robotics and human employees work side by side every day. Two employees infuse about 6,000 joints during an eight-hour shift by hand, costing the company about four cents per joint. The Stardust machine, assuming it is working flawlessly, is marginally cheaper, infusing just as many joints during that shift, each three-and-a-half cents. 'It's worth it if you're about volume,' says Blue Fox Brands founder and CEO Kosta Marselis. 'It does its job basically every single time and makes pretty joints.' But when you factor in the hour it takes to clean the Stardust between batches of different types of joints and the fact that the Stardust wastes more THC oil and kief than human infusers do, Marselis says the output between human and machine is 'basically the same.' In a state like Michigan, the $250,000 investment for the Stardust is worth it because the price of oil is low, about $1,000 per liter, and the market can handle the machine's high volume. But Marselis says he probably won't buy a Stardust for his operations in Massachusetts, where the price of THC oil is $4,000 and the market cannot handle as much volume. P artansky is not a traditional weed entrepreneur—he is a robotics nerd. These days, he usually takes edibles to help him sleep but will occasionally hit a joint, especially one that was made by one of his machines. Born in Manhattan and raised in Los Angeles, he became a professional Magic The Gathering player in high school. 'I was really into Magic, at, like, an uncomfortable level,' he says. He attended University of California-Davis for mechanical engineering in 2013 and graduated from Georgia Tech with a master's degree in aerospace engineering in 2015. His first job was an internship at XCor Aerospace, a private space flight startup in the Mojave Desert. While there, he realized that rocket science was 'less magic and more kitchen sink,' he says, and that the founders of the company were very smart, but not unattainable geniuses. After launching his first company—Lathon, a 3D printing firm—while getting his masters, he landed a job at NASA's Jet Propulsion Laboratory, working on the MOXIE project, a device that produces oxygen on Mars. But he soon got the itch to start a new company, one closer to his heart. In 2018, he launched Sorting Robotics to first make a machine that organized Magic The Gathering playing cards, a process that can take days to do manually. 'Sorting cards was the bane of everyone's existence,' he says. But Partanksy and his cofounders wanted to build a company with a larger potential market than a 'children's trading card game,' he says. At the end of 2018, the trio applied to the startup accelerator Y Combinator and got accepted. They spent five months cold-calling companies in different sectors, looking for one that was ripe for automation. That's when they came across the cannabis industry. 'We had friends who had just started legal cannabis companies, and they basically said, 'Hey, there is zero automation in this space, just build anything,'' Partansky remembers. 'We didn't really know what we were doing, but we identified the problem set. At the end of 2019, we raised a few million dollars out of demo day to go after the cannabis market.' With $3.5 million in funding from Splash Capital, Night Owl Ventures and Genesis Ventures, the founders sold their Magic The Gathering card sorting company for a nominal amount and launched a cannabis manufacturing and packaging business, in Oakland to learn about the industry. They soon realized infused pre-rolls were popular but time-consuming to make by hand. (Partansky sold the co-packing business to a dispensary chain in 2022 after the California weed market started tanking.) After a couple years of development, the trio launched their first cannabis robot in 2021: the Jiko, which infuses joints with THC through an injection process—a needle filled with cannabis concentrate fills the inside of the joint with mind-bending rosin or distillate. It sells for $90,000 and can infuse 1,000 joints an hour. The next year, Sorting Robotics launched the Omnifiller, a $150,000 machine that can fill 6,000 vape carts with THC concentrate an hour. Last year, Sorting put the Stardust on the market, its most advanced and most expensive robot yet. For Partansky, the path from NASA to weed robots was less of an aha moment and more of a slow, iterative process, something he learned while working on the Mars rover. Today, he believes Sorting Robotics has a culture that is a mashup of a federally funded high-tech firm and a fast-moving tech darling. 'Sorting Robotics is like if NASA and Facebook had a baby,' Partansky says, without a tinge of irony considering his company is microscopic compared to either of those two behemoths. 'We ship things fast and don't break anything. Robots are expensive—don't break the robot.' There are a handful of competitors in the cannabis robotics industry, from Action Pack to Accelerant to Roll Pros. But the real giants—the companies that make cigarette manufacturing equipment —have largely remained on the sidelines. Germany-based Körber (2024 sales: $3.2 billion) has been producing cigarette rolling machines, which can make 20,000 cigarettes per minute, for 79 years. The company recently expanded into the hemp market with its Nano-H machine, which can roll 5,000 joints per minute at a cost of two cents each. Partanksy says joints, and especially infused joints, are too specialized ('It grinds differently. It burns differently. It's fabricated differently,' he says.) for these machines to take over the marijuana industry just yet, but its more likely the big boys are wary of entering a market that remains illegal at the federal level. But Big Tobacco—and its highly efficient rolling machines—will come for cannabis when legalization finally arrives. The federal government may soon restart the stalled marijuana rescheduling process that was started under President Joe Biden. In early August, during a press conference at the White House, President Donald Trump said: 'we'll make a determination over the next few weeks." The process could end with marijuana being reclassified from a Schedule I drug (alongside heroin and LSD) to a Schedule III drug (think Tylenol with codeine). That would help the industry because it would give pot companies full access to the American financial system. If weed is rescheduled to a more lenient category, Partansky envisions a future in which cigarette machine manufacturers would look for an easy way to get into the burgeoning cannabis industry – and his company is very much for sale. 'It could go federal between now and the next five years at any point in time,' says Partansky. 'And I think when it does that, the tobacco companies or manufacturers that service those industries don't have any market share in this industry. So, they're just going to come in and buy me.' More from Forbes Forbes Zyn, But With Weed: The Pouch Craze Hits The Cannabis Industry By Will Yakowicz Forbes Inside Stiiizy, The World's Best-Selling Weed Brand By Will Yakowicz Forbes Why One-Time Cannabis Darling Tilray Is Now High On Beer By Will Yakowicz Forbes The Kings Of CBD Are Now Cooking Up Plans To Make Billion-Dollar Meds From Cannabis And Mushrooms By Will Yakowicz
Business Wire
2 days ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
